Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy
NCT ID: NCT00997633
Last Updated: 2009-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
1991-05-31
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
NCT07127627
Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer
NCT01359267
Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer
NCT04778345
Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
NCT00620243
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
NCT03220217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Peritoneal carcinomatosis
Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single-Photon Emission Computed Tomography (SPECT) before the second course of treatment
14 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dept of Surgical Sciences, Section of Surgery, Uppsala University, Sweden
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haile Mahteme, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Dept of Surgical Sciences, University Hospital, Uppsala, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept of Surgical Sciences, Section of Surgery
S-751 85 Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPECT IK1991:5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.